Table 2.

Characteristics of the vaccinated cohort, stratified by age and gender.

Characteristics	mRNA-1273 < 48 Female	BNT162b2 < 48 Female	mRNA-1273 < 48 Male	BNT162b2 < 48 Male	mRNA-1273 > 48 Female	BNT162b2 > 48 Female	mRNA-1273 > 48 Male	BNT162b2 > 48 Male
Volunteers, n	26	37	6	3	28	34	8	8
Ethnicity, n (%)
Caucasian	24 (92.3)	35 (94.6)	6	3	27 (96.4)	32 (94.1)	8	8
Latin-American	2 (7.7)	2 (5.4)	0	0	1 (3.6)	2 (5.9)	0	0
Comorbidities, n (%)
Hyperthyroidism	0	1 (2.7)	0	0	0	0	0	0
Hypothyroidism	2 (7.7)	0	0	0	3 (10.7)	1 (2.9)	0	0
Hypertension	0	0	0	1 (33.3)	4 (14.3)	2 (5.9)	1 (12.5)	0
Dyslipidemia	0	0	0	0	2 (7.1)	3 (8.8)	1 (12.5)	1 (12.5)
Hypercholesterolemia	0	1 (2.7)	0	0	0	1 (2.9)	0	0
Diabetes	0	0	0	0	0	1 (2.9)	0	0
Pulmonary disease	2 (7.7)	1 (2.7)	0	0	2 (7.1)	1 (2.9)	1 (12.5)	0

Characteristics of the cohort vaccinated with mRNA-1273 or BNT162b2, stratified by age and gender. We calculated the median age to be 48 years. We decided to divide the volunteers into several sub-groups: mRNA-1273 < 48 female, BNT162b2 < 48 female, mRNA-1273 < 48 male, BNT162b2 < 48 male, mRNA-1273 > 48 female, BNT162b2 > 48 female, mRNA-1273 > 48 male and BNT162b2 > 48 male. Listed are the number of patients for each group and characteristics such as ethnicity and comorbidities.